Key result
Probucol treatment reduced LDL-C in 71% of patients with hypercholesterolemia, which significantly correlated with baseline LDL-C levels (r = 0.64; p < 0.0001).
Why the study?
Does probucol reduce LDL-C and inhibit carotid atherosclerosis progression in patients with hypercholesterolemia?
Population
140 patients with hypercholesterolemia attending a single Lipid Clinic
Comparison
Probucol 0.5 g twice daily for at least 6 months vs Matched patients with hypercholesterolemia…
Design
Cohort
Follow-up
at least 6 months (24 months for ultrasound subset)
Authors
Loading...
LDL-C reductions with probucol in hypercholesterolemia merit prospective validation; leaves open effects on carotid atherosclerosis.
Observational (n=140)
No
Does probucol reduce LDL-C and inhibit carotid atherosclerosis progression in patients with hypercholesterolemia?
Effect estimate: r = 0.64
p-value: p=< 0.0001
Probucol effectively lowers LDL-C and may halt carotid atherosclerosis progression, particularly in patients with combined elevations of LDL-C and HDL-C.
Baldassarre et al. (1997) conducted an observational in Hypercholesterolemia (n=140). Probucol vs. Baseline / matched patients receiving other lipid-lowering regimens was evaluated on Reduction of low-density lipoprotein cholesterol (LDL-C) (r = 0.64, p=< 0.0001). Probucol treatment reduced LDL-C in 71% of patients with hypercholesterolemia, which significantly correlated with baseline LDL-C levels (r = 0.64; p < 0.0001).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: